Abstract
Sharing both innate and adaptive immune properties, γδT cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as γδT cells represents one such approach. γδT cells can be modified using many of the techniques used in αβT cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from γδT cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, γδT cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
Highlights
Cellular engineering has offered many options for redirecting immune responses against cancer
Viral or transposon-based gene transfer generates stable construct expression over time by integrating into the transduced cell genome. This has been considered important in the chimeric antigen receptor (CAR)-T cell field as it allows for persistence of CAR-T cells for weeks or months
While there is promising data to suggest that gene-modified γδT cells may be an attractive candidate for clinical studies, the bulk of enthusiasm in the cellular immunotherapy field focuses on αβT cells
Summary
Reviewed by: Martin Wilhelm, Klinikum Nürnberg, Germany Drew C. Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology. Sharing both innate and adaptive immune properties, γδT cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. ΓδT cells can be modified using many of the techniques used in αβT cell engineering, with the added advantage of innate-like tumor recognition and killing. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, γδT cells may offer an attractive chassis to drive anti-tumor responses that are broader, and possess a more favorable safety profile
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
